B of A Securities Maintains Neutral on 10x Genomics, Raises Price Target to $30
10x Genomics
10x Genomics TXG | 0.00 |
B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:
TXG) with a Neutral and raises the price target from $21 to $30.
